Anika Therapeutics, Inc. :ANIK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 1, 2017

Anika Therapeutics, Inc. reports financial results for the quarter ended March 31, 2017.

We analyze the earnings along side the following peers of Anika Therapeutics, Inc. – Medtronic plc, Zimmer Biomet Holdings, Inc., Dynatronics Corporation, STAAR Surgical Company, Valeant Pharmaceuticals International Inc, Johnson & Johnson, Halozyme Therapeutics, Inc., Stryker Corporation and Hill-Rom Holdings, Inc. (MDT-US, ZBH-US, DYNT-US, STAA-US, VRX-US, JNJ-US, HALO-US, SYK-US and HRC-US) that have also reported for this period.

Highlights

  • Summary numbers: Revenues of USD 23.39 million, Net Earnings of USD 5.49 million.
  • Gross margins narrowed from 75.65% to 73.99% compared to the same period last year, operating (EBITDA) margins now 38.57% from 52.29%.
  • Year-on-year change in operating cash flow of 101.30% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Narrowing of operating margins contributed to decline in earnings.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31
Relevant Numbers (Quarterly)
Revenues (mil) 23.39 28.73 25.79 26.58 22.28
Revenue Growth (%YOY) 4.95 -7.02 8.9 16.06 43.57
Earnings (mil) 5.49 8.09 8.95 8.62 6.9
Earnings Growth (%YOY) -20.33 -26.78 6.83 10.17 96.13
Net Margin (%) 23.49 28.15 34.71 32.41 30.94
EPS 0.37 0.54 0.59 0.57 0.45
Return on Equity (%) 9.7 14.79 17.09 17.24 13.58
Return on Assets (%) 9.01 13.72 15.78 15.76 12.25

Access our Ratings and Scores for Anika Therapeutics, Inc.

Market Share Versus Profits

Revenues History
Earnings History

ANIK-US‘s change in revenue this period compared to the same period last year of 4.95% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that ANIK-US is holding onto its market share. Also, for comparison purposes, revenues changed by -18.59% and earnings by -32.06% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus

Earnings Growth Analysis

The company’s year-on-year decline in earnings was influenced by a weakening in gross margins from 75.65% to 73.99%, as well as issues with cost controls. As a result, operating margins (EBITDA margins) went from 52.29% to 38.57% in this time frame. For comparison, gross margins were 73.76% and EBITDA margins were 47.68% in the previous period.

Gross Margin Versus EBITDA Margin

Quadrant label definitions. Hover to know more

Differentiated; Low Cost, Commodity; Low Cost, Commodity; High Cost, Differentiated; High Cost

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

ANIK-US‘s decline in gross margins has not produced any significant offsetting improvement in its working capital . This leads Capital Cube to conclude that the decline in gross margins are likely from operating issues and not trade-offs with the balance sheet. Working capital days are currently 639.08 days, compared to last year’s level of 604.79 days.

Gross Margin Versus Working Capital Days

Quadrant label definitions. Hover to know more

Customer Financed, Cash Starved, Supplier Financed, Cash Rich

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

ANIK-US‘s change in operating cash flow of 101.30% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings

Margins

The company’s decline in earnings has been influenced by the following factors: (1) Decline in operating margins (EBIT margins) from 48.06% to 34.23% and (2) one-time items that contributed to a decrease in pretax margins from 48.38% to 34.48%

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for Anika Therapeutics, Inc.

Company Profile

Anika Therapeutics, Inc. is global medical technology company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration and wound healing. The company’s products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical and veterinary. Anika Therapeutics was founded in 1992 and is headquartered in Bedford, MA.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of ANIK-US.